新しい画像エージェントが前立腺がんの再発を早期に検出し,PSAレベルが低い男性の基準より正確だった。 A new imaging agent detected prostate cancer recurrence earlier and more accurately than the standard in men with low PSA levels post-surgery.

Clarity Pharmaceuticalsは,同PSMA第2期試験が主要エンドポイントを達成したと発表し,64Cu- SAR- bisPSMA PET/CTが前立腺手術後の低PSAレベル (0. 20. 75 ng/ mL) の50人の男性で,標準の68Ga- PSMA-11よりも,PSMA陽性病変を有意に多く検出したと示した. Clarity Pharmaceuticals announced its Co-PSMA Phase II trial met its primary endpoint, showing 64Cu-SAR-bisPSMA PET/CT detected significantly more PSMA-positive lesions than standard 68Ga-PSMA-11 in 50 men with low PSA levels (0.2–0.75 ng/mL) after prostate surgery. 新しい画像エージェントは,更に多くの病変を特定し,更に6ヶ月前に再発を検出した. The new imaging agent identified more lesions, including those as small as 2 mm, and detected recurrence up to six months earlier, with better tumor-to-background ratios. この結果は,以前のCOBRA試験の発見と一致し,64Cu- SAR- bisPSMAを優れた診断薬として支持し,二つのFast Track指定と進行中の登録試験によって裏付けられています. Results align with prior COBRA trial findings and support 64Cu-SAR-bisPSMA as a superior diagnostic, backed by two Fast Track Designations and ongoing registrational trials. 今後の会議で完全なデータが提示される. Full data will be presented at an upcoming conference.